Tag:
Eloxatin
Latest Headlines
Latest Headlines
Top 10 Best-selling Cancer Drugs in 2011
Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development.
Sanofi CEO: Look out below, profits are falling
It wasn't Sanofi's fourth-quarter profits, which grew by 13%. Nor was it the 8.8% increase in sales for the period, or the 5.3% increase in 2011 sales, to €33.39 billion ($44.3...
U.S. court affirms Sanofi's Eloxatin patent until 2012
Sanofi's ( $SNY ) Eloxatin is safe from generic competition in the U.S. until August 2012. A federal court denied Sun Pharmaceuticals' appeal in a patent dispute over the colon cancer drug, which
Sanofi prevails over Sun's generic Eloxatin
Sanofi-Aventis has reason to cheer a U.S. court decision today: A judge has banned Sun Pharmaceuticals from selling generic versions of its cancer drug Eloxatin until mid-2012. The ruling makes Sun
Eloxatin patent round goes to Sanofi
Sanofi-Aventis has won a somewhat academic victory in the Eloxatin patent fight. A Circuit Court threw out a ruling against Sanofi's Eloxatin patent rights, remanding the fight back to trial court.
Appeals court halts Eloxatin copycats
Stop that generic Eloxatin shipment! A U.S. appeals court suspended approvals of copycat forms of Sanofi-Aventis' cancer treatment, reviving the drugmaker's efforts to fight generic rivals. Sanofi
